Rocket Lab's $2.2B Backlog Can't Shield Stock as Insiders Cash In and Neutron Slips
05.06.2026 - 17:50:27 | boerse-global.de
Four Rocket Lab insiders have cashed out $18 million in stock this week, sending a jolt through a market already unnerved by the delayed debut of the Neutron rocket. The sell-off has clipped more than 15% from the share price in seven days, leaving the stock at €100.40 — about 25% below its 52-week high reached just two weeks ago. Yet the company's order book has never been fatter, and at least one analyst has slapped a fresh Street-high price target on the name.
Director Alexander Slusky led the insider exodus, unloading 60,000 shares for nearly $9 million. President Marvin Clevenger, COO Frank Klein and General Counsel Arjun Kampani all followed suit, executing sales through pre-arranged 10b5-1 plans. CFO Adam Spice did not sell but transferred 188,172 shares to trusts where he serves as trustee — a move that some interpret as a quiet signal. The combined $18 million tally is notable even after a period of blistering gains: Rocket Lab stock has more than quadrupled over the past twelve months and is up roughly 59% since the start of the year.
Against that backdrop, Stifel's Erik Rasmussen raised his price target to $132 from $110 — the highest on the Street. Rasmussen, ranked 117th out of more than 12,000 analysts on TipRanks with a 75% hit rate, cited strong revenue momentum, a swelling backlog and an accelerating Electron launch cadence. Stifel now views the Electron rocket as a scalable, cash-generating platform, while the Space Systems division provides stable multi-year government contracts. "Neutron execution will be the primary driver for further valuation gains," Rasmussen wrote.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Indeed, the operational story remains compelling. First-quarter revenue hit a record $200.3 million, up 63.5% year-over-year, and the backlog reached $2.2 billion — more than double the level a year ago. Management expects second-quarter revenue between $225 million and $240 million. Yet the bottom line is still red: a net loss of $45 million in Q1, though losses are shrinking and margins improving. With over $1 billion in net cash, Rocket Lab has ample runway.
Neutron, the company's next-generation medium-lift rocket, is the big catalyst — and the big question mark. A crack in the first-stage tank forced a delay of the maiden flight to the fourth quarter of 2026, pushing a key inflection point further out. Meanwhile, the company is not standing still. On June 10, it plans a suborbital test flight under the HASTE program from Launch Complex 2 in Virginia. And earlier this month, Rocket Lab passed the System Requirements Review for the Space Development Agency's Tranche 3 tracking-layer constellation, a critical milestone on the path to becoming a prime contractor for national security satellites.
The sector-wide sentiment took a hit after S&P Dow Jones Indices denied SpaceX rapid entry into the S&P 500 on June 4, citing non-GAAP profitability — SpaceX posted a net loss of nearly $5 billion on $18.7 billion in 2025 revenue. The decision rattled investors who had priced in a valuation lift from a SpaceX listing, and the downdraft swept across space-infrastructure names including Rocket Lab.
But the sell-off may be more about sentiment than substance. The stock's relative strength index now sits at 51.4, neutral territory after the recent rout. With a record backlog, rising sales and a debutant rocket still on the runway for later this year, the next real test comes with Q2 earnings. If Rocket Lab confirms its guidance of up to $240 million in quarterly revenue, the current pullback could prove to be exactly what it looks like: a sector-driven correction, not a reassessment of the growth story.
Ad
Rocket Lab Stock: New Analysis - 5 June
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
